This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Awan, N. A. Articles by Mason, D. T. Search for Related Content PubMed PubMed Citation Articles by Awan, N. A. Articles by Mason, D. T.

Circulation, Vol 56, 346-354, Copyright © 1977 by American Heart Association

ARTICLES

Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography

NA Awan, RR Miller, AN DeMaria, KS Maxwell, A Neumann and DT Mason

The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease. Ventricular function was assessed by cardiac catheterization, echocardiography, and treadmill testing; symptomatic evaluation was carried out for two to four months. One hour following 2- 7 mg PZ, control left ventricular filling pressure was reduced (32 to 18 mm Hg, P less than 0.001) and cardiac index was elevated (1.95 to 2.89 L/min/m2, P less than 0.001) for a 6-hour period. After two weeks of PZ 2 to 7 mg four times daily, echographic end-diastolic dimension fell (5.7 to 5.4 cm, P less than 0.001) while shortening fraction increased (27.6 to 30.2%, P less than 0.005). Treadmill exercise duration increased from 209 to 317 seconds (P less than 0.001). Symptoms diminished throughout the duration of follow-up (mean 94 days) with improvement in NYHA functional class (3.7 to 2.2, P less than 0.001). Thus, prazosin possesses sustained nitroprusside-like balanced dilator actions on the systemic arterial and venous systems and is effective in the ambulatory management of chronic severe heart failure.

This article has been cited by other articles:

				J. N. Cohn Left Ventricle and Arteries : Structure, Function, Hormones, and Disease Hypertension, February 1, 2001; 37(2): 346 - 349. [Abstract] [Full Text] [PDF]

				L. Gould, C. Gopalaswamy, F. Chandy, and O. Abdou Noninvasive Assessment of Left Ventricular Wall Stress in Chronic Congestive Heart Failure Patients Angiology, February 1, 1983; 34(2): 111 - 118. [Abstract] [PDF]

				W. S. COLUCCI Alpha-Adrenergic Receptor Blockade with Prazosin: Consideration of Hypertension, Heart Failure, and Potential New Applications Ann Intern Med, July 1, 1982; 97(1): 67 - 77. [Abstract] [PDF]

				D. T. Mason, N. A. Awan, J. A. Joye, G. Lee, A. N. DeMaria, and E. A. Amsterdam Treatment of Acute and Chronic Congestive Heart Failure by Vasodilator-Afterload Reduction Arch Intern Med, December 1, 1980; 140(12): 1577 - 1581. [Abstract] [PDF]

				S. B. ARNOLD, R. L. WILLIAMS, T. A. PORTS, R. A. BAUGHMAN, L. Z. BENET, W. W. PARMLEY, and K. CHATTERJEE Attenuation of Prazosin Effect on Cardiac Output in Chronic Heart Failure Ann Intern Med, September 1, 1979; 91(3): 345 - 349. [Abstract] [PDF]

				P. Reyns, D. Romney, K. B. Desser, and A. Benchimol Serial Hemodynamic Studies During the Treatment of Congestive Heart Failure With Isolated Low-Dose Oral Prazosin Therapy Angiology, January 1, 1979; 30(12): 850 - 855. [Abstract] [PDF]

				L. J. Laslett, A. N. DeMaria, E. A. Amsterdam, and D. T. Mason Hydralazine-Induced Tachycardia and Sodium Retention in Heart Failure: Hemodynamic and Symptomatic Correction by Prazosin Therapy Arch Intern Med, May 1, 1978; 138(5): 819 - 820. [Abstract] [PDF]